Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Eliezer M. Van Allen, Kent William Mouw, Philip Kim et al. · Cancer Discovery · 2014
UNLABELLED: Cisplatin-based chemotherapy is the standard of care for patients with muscle-invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely understood. We performed whole-exome sequencing on pretreatment tumor and germline DNA from 50 patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy (25 pT0/pTis "responders," 25 pT2+ "nonresponders") to identify somatic mutations that occurred preferentially in responders. ERCC2, a nucleotide excision repair gene, was the only significantly mutated gene enriched in the cisplatin responders compared with nonresponders (q < 0.01). Expression of representative ERCC2 mutants in an ERCC2-deficient cell line failed to rescue cisplatin and UV sensitivity compared with wild-type ERCC2. The lack of normal ERCC2 function may contribute to cisplatin sensitivity in urothelial cancer, and somatic ERCC2 mutation status may inform cisplatin-containing regimen usage in muscle-invasive urothelial carcinoma. SIGNIFICANCE: Somatic ERCC2 mutations correlate with complete response to cisplatin-based chemosensitivity in muscle-invasive urothelial carcinoma, and clinically identified mutations lead to cisplatin sensitivity in vitro. Nucleotide excision repair pathway defects may drive exceptional response to conventional chemotherapy.
Cited by 620 works. doi:10.1158/2159-8290.cd-14-0623
Authors
- Eliezer M. Van Allen
- Kent William Mouw
- Gopa Iyer
- Nikhil Wagle
- Hikmat A Al‐Ahmadie
- Cong Zhu
- Irina Ostrovnaya
- Gregory V. Kryukov
- Kevin W. O’Connor
- John P. Sfakianos
- Ilana Rebecca Garcia-Grossman
- Jaegil Kim
- Elizabeth Ann Guancial
- Richard Martin Bambury
- Samira Bahl
- Namrata Gupta
- Deborah Norman Farlow
- Angela Q. Qu
- Sabina Signoretti
References
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- A method and server for predicting damaging missense mutations
- Integrative genomics viewer
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
- Discovery and saturation analysis of cancer genes across 21 tumour types
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
- A Landscape of Driver Mutations in Melanoma
- Comprehensive molecular characterization of urothelial bladder carcinoma